This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

BayerPRO Case Studies | PP-PF-OTH-GB-0077, August 2024

Women's Health
Oncology

PP-PF-OTH-GB-0077 | August 2024

nmCRPC Patient Case Study
NUBEQA® (darolutamide) - A Urologist Perspective
PP-NUB-GB-2038, January 2025
nmCRPC Patient Case Study
NUBEQA® (darolutamide) - A Clinical Nurse Specialist Perspective
PP-NUB-GB-2046, January 2025
nmCRPC Patient Case Study
NUBEQA® (darolutamide) - A Pharmacist Perspective
PP-NUB-GB-2028, January 2025
nmCRPC Patient Case Study
NUBEQA® (darolutamide) - An Oncologist Perspective
PP-NUB-GB-2031, January 2025
Patient case study: The forgetful pill taker
Discussion who wants to find a contraceptive method that will suit her busy student lifestyle.
PP-PF-WHC-IUS-GB-0022, February 2024
Patient case study: Anxious about hormones
Discussion on counselling a patient anxious about hormones and wants a non-hormonal contraceptive option.
Patient Case Study: The Tricky fit
Discussion on a referral with intracervical blocks.
mCRPC Patient Case Study
A Nuclear Medicine perspective - Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0575, June 2024
mCRPC Patient Case Study
An Oncologist Perspective - Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0574, June 2024